Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved ...

Alnylam Pharma (ALNY) stock rocketed higher on Friday after the pharmaceutical company received approval from the U.S. Food and Drug ...

Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...

Soleno Therapeutics is nearing FDA approval for its lead drug, DCCR, targeting Prader-Willi Syndrome, a rare genetic ...

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

The U.S. FDA approved 16 drugs in February, up from 12 in January but still falling short of the 2024 monthly average of 19 approvals. Just two of those were new molecular entities (NMEs), continuing ...

Research shows a small group of participants in an Alzheimer’s study experienced a significant delay in the onset of symptoms ...

Eli Lilly, Adaptimmune, Aurion Biotech, and ImmunityBio had breakthrough medicines and therapies debut in the past year.

There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.

Four presentations for SCY-247 were accepted by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) congress, April 11-15 ... and Drug Administration (FDA) approved ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

The deal caps a turbulent three years for 2seventy bio. The company served as the oncology business of Bluebird Bio until Bluebird spun out 2seventy in 2021.